A secondary analysis of the brepocitinib vs. placebo (VALOR) trial in adult dermatomyositis (DM), demonstrates that the Tyk2/JAK1 inhibitor is superior to placebo in producing rapid and sustained improvements in cutaneous disease activity, pruritus, and skin-related quality of life as early as week 4 with continued improvement through week 52.

The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or ESSPRI symptom scores.

Estrogen-only menopausal hormone therapy was associated with a slightly higher incidence of autoimmune disease compared with estrogen-progestogen therapy, a retrospective cohort study suggested.

Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines. These guidelines emphasize earlier specialist input, methotrexate as an option, and bone protection for all PMR patients who will require chronic glucocorticoids.